Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Capital Expenditures (2018 - 2024)

Historic Capital Expenditures for X4 Pharmaceuticals (XFOR) over the last 7 years, with Q4 2024 value amounting to -$3.2 million.

  • X4 Pharmaceuticals' Capital Expenditures fell 916857.14% to -$3.2 million in Q4 2024 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year decrease of 18978.78%. This contributed to the annual value of $326000.0 for FY2024, which is 44333.33% up from last year.
  • X4 Pharmaceuticals' Capital Expenditures amounted to -$3.2 million in Q4 2024, which was down 916857.14% from $3.4 million recorded in Q2 2024.
  • In the past 5 years, X4 Pharmaceuticals' Capital Expenditures ranged from a high of $3.4 million in Q2 2024 and a low of -$3.2 million during Q4 2024
  • Over the past 5 years, X4 Pharmaceuticals' median Capital Expenditures value was $22000.0 (recorded in 2022), while the average stood at $129789.5.
  • Within the past 5 years, the most significant YoY rise in X4 Pharmaceuticals' Capital Expenditures was 4291250.0% (2024), while the steepest drop was 916857.14% (2024).
  • Over the past 5 years, X4 Pharmaceuticals' Capital Expenditures (Quarter) stood at -$690000.0 in 2020, then skyrocketed by 101.88% to $13000.0 in 2021, then surged by 161.54% to $34000.0 in 2022, then grew by 2.94% to $35000.0 in 2023, then tumbled by 9168.57% to -$3.2 million in 2024.
  • Its Capital Expenditures was -$3.2 million in Q4 2024, compared to $3.4 million in Q2 2024 and $59000.0 in Q1 2024.